Found: 6
Select item for more details and to access through your institution.
Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2022, v. 191, n. 1, p. 191, doi. 10.1007/s10549-021-06382-6
- By:
- Publication type:
- Article
Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME).
- Published in:
- Therapeutic Advances in Medical Oncology, 2020, p. 1, doi. 10.1177/1758835920980548
- By:
- Publication type:
- Article
Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort.
- Published in:
- NPJ Breast Cancer, 2021, v. 7, n. 1, p. 1, doi. 10.1038/s41523-021-00252-6
- By:
- Publication type:
- Article
Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database.
- Published in:
- BMC Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12916-023-02754-5
- By:
- Publication type:
- Article
Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database.
- Published in:
- BMC Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12916-023-02754-5
- By:
- Publication type:
- Article
Real‐life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program.
- Published in:
- International Journal of Cancer, 2019, v. 145, n. 12, p. 3359, doi. 10.1002/ijc.32402
- By:
- Publication type:
- Article